ORGO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Organogenesis Holdings Inc. (ORGO) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has shown strong financial growth in the latest quarter, the technical indicators suggest a bearish trend, insider selling is significant, and there are no strong positive catalysts or trading signals. The options data indicates a bearish sentiment, and analysts have reduced confidence in the stock as a top pick for 2026. A hold position is recommended until clearer positive signals emerge.
The MACD is positive and expanding, suggesting some bullish momentum. However, the RSI is neutral, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot point (3.815), with resistance at 3.941 and 4.019, and support at 3.689 and 3.611. Overall, the technical indicators do not strongly support a buy decision.
The company has shown strong financial growth in 2025/Q3, with revenue up 30.98% YoY, net income up 17.79% YoY, and EPS up 22.22% YoY. Analysts still believe the company is well-positioned as a low-cost provider in the market.
Insider selling has increased significantly (1870.37% over the last month), indicating potential lack of confidence among insiders. Analysts have reduced confidence in the stock as a 2026 top pick due to CMS's unexpected decision on Skin-Sub LCDs. The stock's bearish moving averages and lack of recent positive news further weigh against a buy decision.
In 2025/Q3, Organogenesis Holdings Inc. reported strong financial growth: Revenue increased by 30.98% YoY to $150.86M, net income increased by 17.79% YoY to $14.53M, and EPS increased by 22.22% YoY to $0.11. However, gross margin slightly declined by 0.99% YoY to 75.97%.
BTIG maintains a Buy rating with a $9 price target but has reduced confidence in the stock as a 2026 top pick due to regulatory uncertainties. Analysts still believe the company is well-positioned as a low-cost provider but are cautious about recent developments.
